McKinsey & Co. earns spot on Vault’s Consulting Firm Practice Area Rankings for 2012
NEW YORK — McKinsey & Co. has earned multiple honors on Vault.com’s latest Consulting Firm Practice Area Rankings.
McKinsey & Co said it earned the No. 1 spot for management, strategy, energy and healthcare consulting, as well as the No. 2 spot overall with a score of 23.23.
The full rankings can be viewed here.
“Vault’s Practice Area Rankings enable aspiring consultants to make informed decisions that will help them land a job at a top firm that matches their professional interests,” Vault.com director of research and consulting Brian Dalton said. “Finding a firm that offers top notch business expertise will help consultants grow as they continue on their professional path to success.”
Wolters Kluwer Pharma hires Henry Prolog
PHOENIX — Healthcare information provider Wolters Kluwer Pharma has appointed Henry Prolog as its VP data strategy, acquisitions and services, the company said.
The company said Prolog brought more than 25 years of sales, data contracts and marketing experience in the healthcare, technology and information services industries. Before Wolters Kluwer, Prolog worked for IMS Health, Siemens Medical, Fresenius USA and Verispan. Most recently, he was national director for channels at US Oncology in Houston.
"Hank will help us evolve vendor relationships into true partnerships that will fulfill our customer, partner and stakeholder needs," Wolters Kluwer Pharma Solutions president and COO for healthcare analytics Michelle Woker said. "This role is key to our strategy going forward, and Hank’s myriad of experience will help us achieve both our short- and long-term goals."
Studies: Bydureon shows improvements in cardiovascular health
LISBON, Portugal — Patients treated with a long-acting drug for Type 2 diabetes experienced a reduction in cardiovascular health risk factors, according to results of a study presented at the European Association for the Study of Diabetes’ annual meeting.
Amylin Pharmaceuticals, Eli Lilly & Co. and Alkermes said analyses of the "DURATION-3" and "DURATION-4" trials showed that patients treated with Bydureon (exenatide) showed improvements in body weight, blood pressure and lipid levels. Bydureon is a long-acting formulation of the injected drug Byetta.
"Patients with diabetes are at least twice as likely as people without the disease to have heart disease or a stroke," Lilly Diabetes global exenatide medical director James Malone said. "Having other chronic conditions, including obesity, high blood pressure or high cholesterol, further increases this risk."
Patients in the DURATION-3 study received either Bydureon or Sanofi’s Lantus (insulin glargine [rDNA origin]) as well as metformin or metformin with a sulfonylurea, both widely used generic treatments for diabetes. In the DURATION-4 trial, patients received Bydureon, metformin, Takeda’s Actos (pioglitazone hydrochloride) or Merck & Co.’s Januvia (sitagliptin). In both studies, patients treated with Bydureon showed better blood pressure reduction and weight control than those taking the other drugs.